These findings are in agreement with our previous reports, where we reported that a neutral CB1R antagonist (AM6545) has the ability to reduce the HFD-induced upregulation in hepatic eIF2α (Tam et al., 2010), and that hepatic activation of CB1R induces ER stress and contributes to insulin resistance (Liu et al., 2012). The gene discussed is CNR1; the disease is Insulin resistance.